Effects of specific chemotherapy regimens on vascular injury in breast cancer patients after primary and multiple chemotherapy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200066101

Enrollment

Unknown

Registered

2022-11-24

Start date

2022-11-24

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Not

Interventions

The exposed group:Not

The non-exposed group:Not

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria of the experimental group: (1) Patients diagnosed with breast cancer requiring chemotherapy; (consistent with the diagnostic criteria and TNM staging of gastric and intestinal cancer); (2) Patients with first or multiple chemotherapy regimen (paclitaxel + pyritic/doxorubicin + cyclophosphamide); (3) Female patients aged 18-65 years; (4) Expected survival time > 6 months; (5) No abnormal ECG; (6) The body function can tolerate chemotherapy. 2.Inclusion criteria of control group: (1) Patients admitted to hospital for the first time; (2) Aged 18-65 years; (3) Expected survival time > 6 months; (4) No abnormality in electrocardiogram, liver, and kidney function; (5) Patients with good physical function and no other vascular injury-related diseases or surgical history.

Exclusion criteria

Exclusion criteria: 1.Exclusion criteria of the experimental group: (1) Breast cancer patients receiving non-infusion of paclitaxel + pyridoxorubicin + cyclophosphamide chemotherapy; (2) Patients with severe mental disorders who are unable to cooperate; (3) Patients with severe heart, liver and kidney dysfunction; (4) Patients who are allergic or intolerant to chemotherapy drugs; (5) Patients who interrupted chemotherapy for various reasons. 2.Exclusion criteria for control group: (1) Patients with other vascular injury-related diseases and surgical history; (2) Patients with severe mental disorders who are unable to cooperate; (3) Patients with severe heart, liver and kidney dysfunction; (4) Patients with vascular related surgery.

Design outcomes

Primary

Measure	Time frame
Homocysteine;Von Willebrand factor;Thrombomodulin;Nitric Oxide Synthase;Human High mobility group box 1;vascular endothelial growth factor;	—

Countries

China

Contacts

Public ContactGao Hong

The Second Affiliated Hospital of South China University

191661222@qq.com+86 15211827295

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026